Live Breaking News & Updates on Clinical Services At Joii

Stay updated with breaking news from Clinical services at joii. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Kalvista's oral hereditary angioedema drug hits phase III goals

Kalvista Pharmaceuticals Inc. is promising to “change the paradigm” in the treatment of hereditary angioedema, after announcing positive phase III data for its oral on-demand kallikrein inhibitor sebetralstat. Rather than waiting four to five hours to self-administer therapy, as is the case for approved injectable on-demand therapies, there was a median time to dosing of 10 minutes after the start of an attack in the 136-patient placebo-controlled trial. ....

Kalvista Pharmaceuticals Inc , Kalvista Pharmaceuticals , Kalvista Pharmaceuticals Inc , Oral Kallikrein Inhibitor , Hereditary Angioedema , On Demand , Hae Attacks ,

Deficiencies at F699: Emerging Trends in the Enforcement of New Regulations

One of the major changes in the revised regulations included tags for which many skilled nursing facilities were not adequately prepared to address, specifically F699, which addresses the provision of “trauma-informed care.” ....

United States , New York , Timothy Legg , Mental Health Provider Shortage , Full Texts , Informed Care , Most Frequency Cited , What Deficient Practices Were , Health Provider Shortage ,

Street likes Luna wet AMD phase II but Adverum wanes

With Adverum Biotechnologies Inc.’s preliminary safety and efficacy data made public from the ongoing Luna phase II trial testing gene therapy ixoberogene soroparvovec (ixo-vec) in wet age-related macular degeneration (AMD), Wall Street promptly began stacking the results against those of competitors. CEO Laurent Fischer pointed out that ixo-vec boasts the “highest rate of injection-free patients of any study of any program at any dose.” ....

Laurent Fischer , Adverum Biotechnologies Inc , With Adverum Biotechnologies , Wall Street , Adverum Biotechnologies Inc , Ixoberogene Soroparvovec , Wet Age Related Macular Degeneration , Gene Therapy , Diabetic Macular Edema , Anti Vegf , Central Subfield Thickness ,

Synlogic pulls plug after peek at phenylketonuria phase III data

Synlogic Inc. jolted Wall Street with news that the firm is scrapping for futility Synpheny-3, its pivotal study with labafenogene marselecobac (SYNB-1934) for phenylketonuria, and will evaluate strategic options. Shares of the Cambridge, Mass.-based firm (NASDAQ:SYBX) fell 48.7%, or $1.68, to end Feb. 9 at $1.77. Synlogic will cease operations and reduce its workforce by more than 90%, retaining only certain employees to help with the wind-down. ....

United Kingdom , Synlogic Inc , Wall Street , Synlogic Inc , Labafenogene Marselecobac , Synb 1934 , Endocrine Metabolic ,